Recent 8-K filings for APM
Highest-materiality recent filing
Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt
- H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.
- Cash fell to $1,834,171 from $3,452,891 at Dec 31, 2025; operating cash outflow of $1,553,720.
-
Sales Agreement dated October 9, 2026 lets Niki BioSolutions (NIKI) sell up to $1,396,000 of common stock through H.C. Wainwright as sales agent or principal.
-
Niki BioSolutions files corporate presentation for H.C. Wainwright conference
Corporate presentation led by President & COO Alidad Mireskandari, Ph.D. at H.C. Wainwright Global Investment Conference, September 2026.
-
Niki BioSolutions names Ian Huen CEO/Chairman and Alidad Mireskandari President/COO
Ian Huen appointed CEO and Chairman effective Aug 1, 2026; 6-month initial term, HKD 210,000/month (~USD 26,800).
-
Niki BioSolutions closes DiamiR merger; acquired firm posts FY2026 net loss and going-concern doubt
Merger closed July 20, 2026; DiamiR Biosciences became a wholly-owned subsidiary of Niki BioSolutions (formerly Aptorum Group).
-
Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt
H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.
-
Niki BioSolutions regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency letter on March 5, 2026 for bid price below $1.00 for 30 consecutive business days.
-
Aptorum completes merger with DiamiR, redomiciles as Niki BioSolutions, trades under NIKI
Merger closed July 20, 2026; Aptorum redomiciled to Delaware and renamed Niki BioSolutions, Inc.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event m_and_a